留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

神经病理性疼痛的药物治疗进展

赵佳丽,  陈秋红,  李红娜,  曾莉莉,  叶永贤,  费燕

downloadPDF
文章导航 > 药学实践与服务  > 2016 >  34(4): 309-312
赵佳丽, 陈秋红, 李红娜, 曾莉莉, 叶永贤, 费燕. 神经病理性疼痛的药物治疗进展[J]. 药学实践与服务, 2016, 34(4): 309-312. doi: 10.3969/j.issn.1006-0111.2016.04.006
引用本文: 赵佳丽, 陈秋红, 李红娜, 曾莉莉, 叶永贤, 费燕. 神经病理性疼痛的药物治疗进展[J]. 药学实践与服务, 2016, 34(4): 309-312. doi: 10.3969/j.issn.1006-0111.2016.04.006
shu
ZHAO Jiali, CHEN Qiuhong, LI Hongna, ZENG Lili, YE Yongxian, FEI Yan. Progress on drug therapy of neuropathic pain[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(4): 309-312. doi: 10.3969/j.issn.1006-0111.2016.04.006
Citation: ZHAO Jiali, CHEN Qiuhong, LI Hongna, ZENG Lili, YE Yongxian, FEI Yan. Progress on drug therapy of neuropathic pain[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(4): 309-312. doi: 10.3969/j.issn.1006-0111.2016.04.006
shu

神经病理性疼痛的药物治疗进展

doi: 10.3969/j.issn.1006-0111.2016.04.006
  • 1.

    解放军175医院药学科, 福建 漳州 363000

  • 2.

    解放军175医院骨科, 福建 漳州 363000

基金项目: 解放军第一七五医院青年苗圃基金课题（15Y008）

Progress on drug therapy of neuropathic pain

  • 1.

    Department of Pharmacy, No. 175 Hospital of PLA, Zhangzhou 363000, China

  • 2.

    Department of Orthopaedics, No. 175 Hospital of PLA, Zhangzhou 363000, China

  • 摘要: 神经病理性疼痛（NPP）是由一系列感染和神经损伤事件引起的慢性疼痛，其发病率高、病因复杂，严重影响患者的生活质量。尽管临床试验逐渐增多，但NPP的治疗仍存在不足。合理使用不同作用机制和持续时间的药物，是当前治疗NPP的研究热点。针对近年来NPP的药物治疗进展做一总结，为该病的治疗提供依据。
    Abstract: Neuropathic pain (NPP) is a chronic pain that caused by a series of infection and nerve damage events. It has high incidence, complex etiology and seriously affects patients' life quality. Although clinic trials gradually increased, the treatment of neuropathic pain is still insufficient. Recent research focuses on reasonably using drugs of different mechanisms and time of duration. The progress of NPP drugs was reviewed in this paper for providing basis for treatment of neuropathic pain.
  • [1] Attal N, Bouhassira D. Neuropathic pain:experimental advances and clinical applications[J]. Rev Neurol, 2004, 160(2):199-203.
    [2] Lema MJ, Foley KM, Hausheer FH. Types and epidemiology of cancer-related neuropathic pain:the intersection of cancer pain and neuropathic pain[J]. Oncologist, 2010, 15(Suppl2):3-8.
    [3] Austin PJ, Moalem-Taylor G. The neuro-immune balance in neuropathic pain:involvement of inflammatory immune cells, immune-like glial cells and cytokines[J]. J Neuroimmunol, 2010, 229(1-2):26-50.
    [4] Tremont-Lukats IW, Megeff C, Backonja MM. Anticonvulsants for neuropathic pain syndromes:mechanisms of action and place in therapy[J]. Drugs, 2000, 60(5):1029-1052.
    [5] Freynhagen R, Baron R. The evaluation of neuropathic components in low back pain[J]. Curr Pain Headache Rep, 2009, 13(3):185-190.
    [6] Dharmshaktu P, Tayal V, Kalra BS. Efficacy of antidepressants as analgesics:a review[J]. J Clin Pharmacol, 2012, 52(1):6-17.
    [7] Watson CP, Chipman M, Reed K, et al. Amitriptyline versus maprotiline, in postherpetic neuralgia:a randomized, double-blind, crossover trial[J]. Pain, 1992, 48(1):29-36.
    [8] Jefferies K. Treatment of neuropathic pain[J]. Semin Neurol, 2010, 30(4):425-432.
    [9] Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain:2010 revision[J]. Eur J Neurol, 2010, 17(9):1113-1188.
    [10] Skljarevski V, Desaiah D, Zhang Q, et al. Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain[J]. Diabetes Metab Res Rev, 2009, 25(7):623-631.
    [11] Sultan A, Gaskell H, Derry S, et al. Duloxetine for painful diabetic neuropathy and fibromyalgia pain:systematic review of randomised trials[J]. BMC Neurol, 2008, 8:29.
    [12] Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain:consensus statement and guidelines from the Canadian Pain Society[J]. Pain Res Manag, 2007, 12(1):13-21.
    [13] Dooley DJ, Taylor CP, Donevan S, et al. Ca2+ channel α-2-δ ligands:novel modulators of neurotransmission[J]. Trends Pharmacol Sci, 2007, 28(2):75-82.
    [14] Caraceni A, Zecca E, Bonezzi C, et al. Gabapentin for neuropathic cancer pain:a randomized controlled trial from the Gabapentin Cancer Pain Study Group[J]. J Clin Oncol, 2004, 22(14):2909-2917.
    [15] Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuopathic pain evaluated in a 12-week, randomized, double-blind, multicenter, placebo-controlled trial of flexible-and fixed-dose regimens[J]. Pain, 2005, 115(3):254-263.
    [16] Gilron I, Bailey JM, Tu D, et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain:A double-blind, randomized controlled crossover trial[J]. Lancet, 2009, 374(9697):1252-1261.
    [17] Griggs RB, Bardo MT, Taylor BK. Gabapentin alleviates affective pain after traumatic nerve injury[J]. Neuroreport, 2015, 26(9):522-527.
    [18] Câmara CC, Araújo CV, de Sousa KKO, et al. Gabapentin attenuates neuropathic pain and improves nerve myelination after chronic sciatic constriction in rats[J]. Neurosci Lett, 2015, 607:52-58.
    [19] Baillie JK, Power I. Morphine, gabapentin, or their combination for neuropathic pain[J]. N Engl J Med, 2005, 352(25):2650-2651.
    [20] García de Paredes ML, del Moral González F, Martínez del Prado P, et al. First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients results of oncology study[J]. Ann Oncol, 2011, 22(4):924-930.
    [21] Sindrup SH, Andersen G, Madsen C, et al. Tramadol relieves pain and allodynia in polyneuropathy:a randomized, double-blind, controlled, trial. Pain, 1999, 83(1):85-90.
    [22] Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain:an overview and literature update[J]. Mayo Clin Proc,2010,85(3):S3-S14.
    [23] Suzuki R, Matthews EA, Dickenson AH. Comparison of the effects of MK-801, ketamine and memantine on responses of spinal dorsal horn neurones in a rat model of mononeuropathy[J]. Pain, 2001, 91(1-2):101-109.
    [24] Vadivelu N, Hines RL. Buprenorphine:a unique opioid with broad clinical applications[J]. J Opioid Manag, 2007, 3(1):49-58.
    [25] Vadivelu N, Hines RL. Management of chronic pain in the elderly:focus on transdermal buprenorphine[J]. Clin Interv Aging, 2008, 3(3):421-430.
    [26] Johnson RE, Fudala PJ, Payne R. Buprenorphine:considerations for pain management[J]. J Pain Symptom Manage, 2005, 29(3):297-326.
    [27] Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain[J]. J Pain, 2009, 10(2):113-130.
    [28] 神经病理性疼痛诊疗专家组. 神经病理性疼痛诊疗专家共识[J]. 中国疼痛医学杂志,2013,19(12):705-710.
    [29] Müller-Schwefe G, Jaksch W, Morlion B, et al. Make a change:optimizing communication and pain management decisions[J]. Curr Med Res Opin, 2011, 27(2):481-488.
  • [1] 王宏播, 卞康晴, 郭灵怡, 代宇, 俞媛.  外泌体用于疾病诊疗和药物递送的研究进展 . 药学实践与服务, 2023, 41(5): 265-272, 320. doi: 10.12206/j.issn.2097-2024.202207022
    [2] 龚晓斌, 刘诗怡, 夏天一, 位华, 陈万生.  阿帕替尼在恶性肿瘤治疗中的临床应用与研究进展 . 药学实践与服务, 2018, 36(2): 103-107,130. doi: 10.3969/j.issn.1006-0111.2018.02.002
    [3] 卞莹莹, 王洁, 李安, 开国银, 陆一鸣.  炎症性肠病的药物治疗现状 . 药学实践与服务, 2017, 35(3): 197-200,228. doi: 10.3969/j.issn.1006-0111.2017.03.002
    [4] 雷永芳, 凌青.  良性前列腺增生症的药物治疗及个体化用药 . 药学实践与服务, 2017, 35(5): 447-448,456. doi: 10.3969/j.issn.1006-0111.2017.05.015
    [5] 马宗强, 安洪亮.  门诊口服抗高血压药物的调查分析 . 药学实践与服务, 2016, 34(2): 188-190,192. doi: 10.3969/j.issn.1006-0111.2016.02.024
    [6] 陈开宇, 江丽萍, 陈盛新.  慢性阻塞性肺疾病的药物治疗进展 . 药学实践与服务, 2012, 30(6): 408-411. doi: 10.3969/j.issn.1006-0111.2012.06.003
    [7] 陈婷, 鲁莹.  载抗肿瘤药物纳米靶向给药系统的研究进展 . 药学实践与服务, 2011, 29(3): 176-178,196.
    [8] 黄景彬, 钟延强.  乳腺癌靶向治疗的新策略 . 药学实践与服务, 2011, 29(5): 324-327.
    [9] 傅翔, 栾智鹏, 陈盛新.  用药安全 . 药学实践与服务, 2009, 27(3): 236-240.
    [10] 丁晴雪, 栾智鹏, 陈盛新.  如何制定、实施和监测药物治疗方案 . 药学实践与服务, 2009, 27(4): 317-320.
    [11] 冯惠坚, 栾智鹏, 陈盛新.  医院药师如何开展循证药物治疗 . 药学实践与服务, 2009, 27(6): 476-480.
    [12] 蒋宁君, 毕新岭, 顾军, 宋书伟.  银屑病的中西医药物治疗近况 . 药学实践与服务, 2008, (6): 412-413,449.
    [13] 薛龙, 孙爱军.  恶性肿瘤靶向治疗方法的进展及应用 . 药学实践与服务, 2008, (2): 81-83.
    [14] 赵民生, 曹秀虹.  利尿剂在治疗心血管疾病时的不良反应及处理 . 药学实践与服务, 2006, (6): 353-354.
    [15] 徐国华, 雷招宝.  治疗慢性丙型肝炎新药——聚乙二醇干扰素α-2b . 药学实践与服务, 2005, (6): 350-353.
    [16] 唐斌, 何佩珍, 徐帆, 尚北城.  黄连素的联合用药 . 药学实践与服务, 2005, (5): 278-281.
    [17] 郭随章.  糖尿病周围神经病变的药物治疗 . 药学实践与服务, 2003, (3): 131-133.
    [18] 田维荣, 戴飞龙, 晏马成.  糖尿病的药物治疗 . 药学实践与服务, 2002, (3): 137-140.
    [19] 张丽梅, 王卓, 徐慧欣, 杨樟卫, 胡晋红.  复发性口腔溃疡的药物治疗 . 药学实践与服务, 2001, (3): 140-142.
    [20] 张生大.  双嘧达莫与其它药物合用的新用途 . 药学实践与服务, 2001, (1): 13-13.
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  3040
  • HTML全文浏览量:  329
  • PDF下载量:  851
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-12-28
  • 修回日期:  2016-01-08

神经病理性疼痛的药物治疗进展

doi: 10.3969/j.issn.1006-0111.2016.04.006
  • 1. 解放军175医院药学科, 福建 漳州 363000
  • 2. 解放军175医院骨科, 福建 漳州 363000
    • 基金项目:  解放军第一七五医院青年苗圃基金课题（15Y008）
  • 收稿日期: 2014-12-28
  • 修回日期: 2016-01-08

摘要: 神经病理性疼痛（NPP）是由一系列感染和神经损伤事件引起的慢性疼痛，其发病率高、病因复杂，严重影响患者的生活质量。尽管临床试验逐渐增多，但NPP的治疗仍存在不足。合理使用不同作用机制和持续时间的药物，是当前治疗NPP的研究热点。针对近年来NPP的药物治疗进展做一总结，为该病的治疗提供依据。

English Abstract

赵佳丽, 陈秋红, 李红娜, 曾莉莉, 叶永贤, 费燕. 神经病理性疼痛的药物治疗进展[J]. 药学实践与服务, 2016, 34(4): 309-312. doi: 10.3969/j.issn.1006-0111.2016.04.006
引用本文: 赵佳丽, 陈秋红, 李红娜, 曾莉莉, 叶永贤, 费燕. 神经病理性疼痛的药物治疗进展[J]. 药学实践与服务, 2016, 34(4): 309-312. doi: 10.3969/j.issn.1006-0111.2016.04.006
shu
ZHAO Jiali, CHEN Qiuhong, LI Hongna, ZENG Lili, YE Yongxian, FEI Yan. Progress on drug therapy of neuropathic pain[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(4): 309-312. doi: 10.3969/j.issn.1006-0111.2016.04.006
Citation: ZHAO Jiali, CHEN Qiuhong, LI Hongna, ZENG Lili, YE Yongxian, FEI Yan. Progress on drug therapy of neuropathic pain[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(4): 309-312. doi: 10.3969/j.issn.1006-0111.2016.04.006
shu

    全文HTML

参考文献 (29)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计